Gerardo TIA, Barrón RJE, Rivera RJA, Álvarez VAS

Language: Spanish
References: 20
Page: 805-813
PDF size: 217.76 Kb.

ABSTRACT

Objective: To identify factors associated with breast cancer recurrence in patients undergoing conservative surgery.
Materials and Methods: Observational, retrospective cohort study conducted on the records of patients with early-stage breast cancer who underwent conservative surgery. Study parameters: stage, histologic subtype, hormone receptor expression profile, follow-up time, recurrence and disease-free period. Statistical analysis was performed to estimate recurrence rate and disease-free period and to identify factors associated with recurrence.
Results: Fifty-three patients with a mean age of 51.0 ± 9.4 years were evaluated. The most common histopathologic subtype was ductal in 49 of 53 patients; tumors were progesterone receptor positive in 48, Her-2 positive in 7 of 53, and triple negative in 3 of 53. The breast cancer recurrence rate was 13.2% (i.e., 7 of 53 patients). Diseasefree time in those who relapsed was 30.6 ± 24.8 months. In bivariate analysis, positive lymph nodes, progesterone and estrogen receptor expression, triple-negative tumors, and adjuvant chemotherapy were significantly associated with recurrence. In multivariate analysis, only having a triple-negative tumor (OR = 51.8; 95%CI: 4.9-548.4; p = 0.001) and receiving chemotherapy (OR = 8.0; 95%CI: 1.4-58.4; p = 0.001) were associated with recurrence.
Conclusion: Factors associated with recurrence were positive lymph nodes, expression of progesterone and estrogen receptors, triple-negative tumors, and receipt of chemotherapy.

REFERENCES

1. OPS. Cáncer de mama. https://www.paho.org/es/temas/cancer-mama

2. Hortobagyi GN, de la Garza Salazar J, Pritchard K, AmadoriD, Haidinger R, Hudis CA, et al. The global breast cancerburden: variations in epidemiology and survival. Clin BreastCancer 2005; 6 (5): 391-401. https://doi.org/10.3816/CBC.2005.n.043

3. Feng Rui-Mei, Zong Yi-Nan, Cao Su-Mei, Rui-Hua Xu. Currentcancer situation in China: good or bad news from the2018 Global Cancer Statistics? Cancer Communications2019; 39 (1): 1-12. https://doi.org/10.1186/s40880-019-0368-6

4. GLOBOCAN. New Global Cancer Data: GLOBOCAN 2018.2018. https://www.iarc.who.int/infographics/globocan-2018-latest-global-cancer-data/

5. Centro Nacional de Equidad de Género y Salud Reproductiva.Información Estadística Cáncer de Mama. Programade acción. 2016. https://www.gob.mx/salud%7Ccnegsr/acciones-y-programas/informacion-estadistica-cancerde-mama

6. Hernández D, Díaz M, Abreu M. Un análisis de largo plazodel comportamiento de la cirugía conservadora del cáncerde mama. Rev Cub Obs Ginecol 2012; 38 (1): 117-33. http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-600X2012000100014&lng=es

7. Min N, Wei Y, Zheng Y, Li X. Advancement of prognosticmodels in breast cancer: a narrative review. Gland Surg2021; 10 (9): 2815-31. doi: 10.21037/gs-21-441

8. Kosir MA. Cáncer de mama. First. Manual MSD. Kenilworth,NJ, USA: Merck Sharp & Dohme 2018; 234-45.

9. Nazmeen A, Chen G, Ghosh TK, Maiti S. Breast cancerpathogenesis is linked to the intra-tumoral estrogen sulfotransferase(hSULT1E1) expressions regulated by cellularredox dependent Nrf-2/NFκβ interplay. Cancer Cell Int 2020(4); 20: 70. doi: 10.1186/s12935-020-1153-y

10. Lafourcade A, His M, Baglietto L, Boutron-Ruault M-C, DossusL, Rondeau V. Factors associated with breast cancer recurrencesor mortality and dynamic prediction of death usinghistory of cancer recurrences: the French E3N cohort. BMCCancer 2018; 18 (1): 171. doi: 10.1186/s12885-018-4076-4

11. Clarke M, Collins R, Darby S, Davies C, Evans V, et al. EarlyBreast Cancer Trialists' Collaborative Group (EBCTCG). Effectsof chemotherapy and hormonal therapy for earlybreast cancer on recurrence and 15-year survival: anoverview of the randomised trials. Lancet 2005; 365 (9472):1687-717. doi: 10.1016/S0140-6736(05)66544-0

12. Villaseñor-Navarro Y. El cáncer de mama en México. Unatarea pendiente. Gac Mex Oncol 2012; 11 (4): 217-9.

13. Luján I, García R, Figueroa P. Menarquia temprana comofactor de riesgo de cáncer de mama. Ginecol Obs Mex2006; 74 (11): 568-72.

14. Jones ME, Schoemaker MJ, Wright LB, Ashworth A, SwerdlowAJ. Smoking and risk of breast cancer in the GenerationsStudy cohort. Breast Cancer Res 2017; 22; 19 (1): 118.doi: 10.1186/s13058-017-0908-4

15. Brewer HR, Jones ME, Schoemaker MJ, Ashworth A,Swerdlow AJ. Family history and risk of breast cancer: ananalysis accounting for family structure. Breast Cancer ResTreat 2017; 165 (1): 193-200. https://pubmed.ncbi.nlm.nih.gov/28578505

16. Ángel J, Mejía A, Guzmán L, Quevedo J, Sánchez R, GarcíaO, et al . Mortalidad y recaída en pacientes con cáncerde mama infiltrante sometidas a cirugía conservadora.Rev colomb cancerol 2015; 19 (1): 18-28. https://doi.org/10.1016/j.rccan.2014.09.002.

17. Bundred JR, Michael S, Stuart B, Cutress RI, Beckmann K,Holleczek B, Dahlstrom JE, Gath J, Dodwell D, Bundred NJ.Margin status and survival outcomes after breast cancerconservation surgery: prospectively registered systematicreview and meta-analysis. BMJ 2022; 378: e070346. doi:10.1136/bmj-2022-070346

18. Montagna E, Bagnardi V, Rotmensz N, Viale G, Renne G,Cancello G, et al. Breast cancer subtypes and outcomeafter local and regional relapse. Annals of Oncology 2012;23 (2): 324-31. doi: 10.1093/annonc/mdr129

19. Martínez-Ramos D, Fortea-Sanchis C, Escrig-Sos J. Relacióndel tamaño tumoral con la recidiva tras cirugía conservadoraen el cáncer de mama en estadio tumoral T1-T2.Estudio poblacional. Cir Cir 2014; 83 (3): 252-61. https://pubmed.ncbi.nlm.nih.gov/25238466/

20. Miles RC, Gullerud RE, Lohse CM, Jakub JW, Degnim AC,Boughey JC. Local recurrence after breast-conserving surgery:multivariable analysis of risk factors and the impactof young age. Ann Surg Oncol 2012; 19 (4): 1153-59. doi:10.1245/s10434-011-2084-6